IDXX Stock - IDEXX Laboratories, Inc.
Unlock GoAI Insights for IDXX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.90B | $3.66B | $3.37B | $3.22B | $2.71B |
| Gross Profit | $2.38B | $2.19B | $2.00B | $1.89B | $1.57B |
| Gross Margin | 61.0% | 59.8% | 59.5% | 58.8% | 58.0% |
| Operating Income | $1.13B | $1.10B | $898.76M | $932.03M | $694.52M |
| Net Income | $887.87M | $845.04M | $679.09M | $744.85M | $581.78M |
| Net Margin | 22.8% | 23.1% | 20.2% | 23.2% | 21.5% |
| EPS | $10.77 | $10.17 | $8.12 | $8.74 | $6.82 |
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $850 |
| October 31st 2025 | Stifel | Upgrade | Buy | $700 |
| October 1st 2025 | UBS | Initiation | Neutral | $720 |
| August 5th 2025 | BTIG Research | Reiterated | Buy | $785← $545 |
| July 1st 2025 | Jefferies | Initiation | Buy | $625 |
| December 2nd 2024 | Leerink Partners | Initiation | Outperform | $500 |
| July 25th 2024 | BTIG Research | Initiation | Buy | $580 |
| January 30th 2024 | Piper Sandler | Downgrade | Neutral | $525 |
| December 7th 2023 | Exane BNP Paribas | Initiation | Outperform | $602 |
| December 4th 2023 | Cleveland Research | Upgrade | Buy | - |
| August 2nd 2023 | Atlantic Equities | Downgrade | Neutral | $610 |
| July 25th 2022 | Stifel | Downgrade | Hold | $415 |
| July 21st 2022 | Goldman | Upgrade | Buy | $435← $530 |
| July 12th 2022 | Piper Sandler | Initiation | Overweight | $440 |
| May 5th 2022 | BofA Securities | Downgrade | Neutral | $470← $550 |
Earnings History & Surprises
IDXXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 2, 2026 | $2.93 | — | — | — |
Q4 2025 | Nov 3, 2025 | $3.14 | $3.40 | +8.3% | ✓ BEAT |
Q3 2025 | Aug 4, 2025 | $3.28 | $3.63 | +10.7% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $2.85 | $2.96 | +3.9% | ✓ BEAT |
Q1 2025 | Feb 3, 2025 | $2.39 | $2.62 | +9.6% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $2.68 | $2.80 | +4.5% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $2.88 | $3.02 | +4.9% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $2.67 | $2.81 | +5.2% | ✓ BEAT |
Q1 2024 | Feb 5, 2024 | $2.12 | $2.32 | +9.4% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $2.37 | $2.53 | +6.8% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $2.47 | $2.67 | +8.1% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $2.42 | $2.55 | +5.4% | ✓ BEAT |
Q1 2023 | Feb 6, 2023 | $1.94 | $2.05 | +5.7% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $2.04 | $2.15 | +5.4% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $1.56 | $1.56 | 0.0% | = MET |
Q2 2022 | May 4, 2022 | $2.26 | $2.27 | +0.4% | ✓ BEAT |
Q1 2022 | Feb 2, 2022 | $1.71 | $1.89 | +10.5% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $1.91 | $2.03 | +6.3% | ✓ BEAT |
Q3 2021 | Jul 30, 2021 | $2.02 | $2.34 | +15.8% | ✓ BEAT |
Latest News
IDEXX Laboratories Promotes Michael Erickson To President And CEO, Effective May 12, 2026, As Jonathan Mazelsky Transitions To Executive Chair
➖ NeutralCNBC Halftime Report Final Trades: Palo Alto Networks, State Street Materials Select Sector SPDR ETF, Capital One Financial, IDEXX Laboratories
➖ NeutralBarclays Initiates Coverage On IDEXX Laboratories with Overweight Rating, Announces Price Target of $850
📈 PositiveMorgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $805
📈 PositiveUBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $750
➖ NeutralJP Morgan Maintains Overweight on IDEXX Laboratories, Raises Price Target to $775
📈 PositiveBTIG Maintains Buy on IDEXX Laboratories, Raises Price Target to $830
📈 PositiveCNBC Halftime Report Final Trades: Meta Platforms, S&P Global , IDEXX Laboratories
➖ NeutralIDEXX Laboratories stock pops on Q3 beats, raised outlook
📈 PositiveIDEXX Laboratories shares are trading higher after the company reported better-than-expected Q3 results and raised its FY2025 EPS and sales guidance.
📈 PositiveIDEXX Laboratories Non-GAAP EPS of $3.22 beats by $0.07, revenue of $1.1B beats by $30M
📈 PositiveIDEXX Laboratories Raises FY2025 GAAP EPS Guidance from $12.40-$12.76 to $12.81-$13.01 vs $12.62 Est; Raises FY2025 Sales Guidance from $4.205B-$4.280B to $4.270B-$4.300B vs $4.232B Est
📈 PositiveIDEXX Laboratories Q3 Adj. EPS $3.22 Beats $3.13 Estimate, Sales $1.105B Beat $1.073B Estimate
📈 PositiveStifel Upgrades IDEXX Laboratories to Buy, Raises Price Target to $700
📈 PositiveUBS Initiates Coverage On IDEXX Laboratories with Neutral Rating, Announces Price Target of $720
➖ NeutralIDEXX rises on upgraded guidance fueled by inVue Dx demand
📈 PositiveIDEXX, DexCom lead S&P 500 healthcare gains in Q2; UnitedHealth and Bristol Myers Squibb among top laggards
📈 PositiveIDEXX Lab jumps after Q1 beat and guidance raise
📈 PositiveFrequently Asked Questions about IDXX
What is IDXX's current stock price?
What is the analyst price target for IDXX?
What sector is IDEXX Laboratories, Inc. in?
What is IDXX's market cap?
Does IDXX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IDXX for comparison